组织型纤溶酶原激活剂及其抑制物的变化与冠心病的关系

目的：观察冠心病患者纤溶活性的变化及其在冠心病发病中的作用，探讨其临床意义。方法：用酶联免疫双抗夹心(ELISA)法测定58例冠心病患者血浆中组织型纤溶酶原激活剂(t—PA)及纤溶酶原激活抑制物-1(PAI-1)抗原含量，反映纤溶-抗纤溶活性的变化，并对冠心病患者组与对照组纤溶指标进行不同性别间的比较。结果：急性心肌梗死、不稳定心绞痛患者PM-1的含量、PAI-1／t—PA比值明显高于对照组，且急性心肌梗死患者PM-1的含量较不稳定心绞痛患者显著为高。但t—PA在急性心肌梗死、不稳定心绞痛患者均无显著降低。患者组及对照组不同性别间纤溶及抗纤溶水平均未见有显著差异。结论：血栓性疾病与纤溶系统的异常有密切关系。纤溶系统活性的变化及纤溶-抗纤溶的平衡失调在缺血性心脏病的发生、发展中起着重要作用。

Changes of Fbrinolytic Parameters in Coronary Heart Disease

Objective: To explore the alterations of fibrinolytic parameters with coronary heart disease(CHD) to elucidate the mechanism of CHD and its clinical significance. Methods: A series of fibrinolytic parameters were measured among 58 cases of CHD using ELISA , including tissue-type plasminogen activator(t-PA) and plasmino-gen activator inhibitor-1(PAI-1). Results: The plasma level of PAl-1 and PAl-1/t-PA were elevated significantly in patients with AMI and UAP than in controls ,PAl1 were higher in patients with AMI than with USP( P < 0. 01). Plasma t-PA antigen was not decreased in patients with AMI and USP. The difference of parameters between male and female was not found. Conclusion: Our results suggest that the alteration of fibrinolytic systems play an important role in the pathogenesis, developing and prognosis of CHD.